HRP20201932T4 - Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba - Google Patents
Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba Download PDFInfo
- Publication number
- HRP20201932T4 HRP20201932T4 HRP20201932TT HRP20201932T HRP20201932T4 HR P20201932 T4 HRP20201932 T4 HR P20201932T4 HR P20201932T T HRP20201932T T HR P20201932TT HR P20201932 T HRP20201932 T HR P20201932T HR P20201932 T4 HRP20201932 T4 HR P20201932T4
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- combination
- ylmethyl
- solvates
- prophylaxis
- Prior art date
Links
- 102000015427 Angiotensins Human genes 0.000 title 1
- 108010064733 Angiotensins Proteins 0.000 title 1
- 101710095468 Cyclase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229940122434 Calcium sensitizer Drugs 0.000 claims 1
- 241000208011 Digitalis Species 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- -1 calcium antagonists Substances 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims 1
- 229960003953 sacubitril Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Kombinacije naznačene time što sadrže sGC stimulator s formulom
[image]
sakubitril i valsartan i također u svakom slučaju i soli, solvate i solvate njihovih soli.
2. Kombinacije prema patentnom zahtjevu 1 naznačene time što sadrže trinatrijev [3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)propionat-(S)-3'-metil-2'-(pentanoil{2"-(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat] hemipentahidrat i također u svakom slučaju i soli, solvate i solvate njihovih soli.
3. Kombinacija prema bilo kojem od zahtjeva 1 ili 2, naznačena time što je za uporabu u postupku za liječenje i/ili profilaksu kardiovaskularnih poremećaja, bubrežnih poremećaja, plućnih poremećaja, kao i za liječenje i/ili profilaksu fibrotičnih poremećaja.
4. Lijek naznačen time što sadrži kombinaciju prema bilo kojem od zahtjeva 1 ili 2, u kombinaciji s inertnim, netoksičnim, farmaceutski prikladnim pomoćnim sredstvom.
5. Lijek koji sadrži kombinaciju prema bilo kojem od zahtjeva 1 ili 2, u kombinaciji s jednim ili više daljnjih aktivnih sastojaka odabranih iz skupine koju čine ACE inhibitori, inhibitori renina, beta blokatori, acetilsalicilna kiselina, diuretici, antagonisti kalcija, statini, derivati digitalisa (digoksin), senzibilizatori kalcija, nitrati i antitrombotici.
6. Lijek koji sadrži kombinaciju prema bilo kojem od zahtjeva 1 ili 2 naznačen time što je za uporabu u postupku za liječenje i/ili profilaksu kardiovaskularnih poremećaja, bubrežnih poremećaja, plućnih poremećaja, kao i za liječenje i/ili profilaksu fibrotičnih poremećaja.
7. Komplet naznačen time što sadrži farmaceutski pripravak koji sadrži sGC stimulator s formulom
[image]
i farmaceutski pripravak koji sadrži valsartan i N-(3-karboksi-1-oksopropil)-(4S)-(p-fenilfenilmetil)-4-amino-2R-metilbutansku kiselinu ili njen ester.
8. Komplet prema patentnom zahtjevu 7 naznačen time što sadrži farmaceutski pripravak koji sadrži sGC stimulator s formulom
[image]
i farmaceutski pripravak koji sadrži trinatrijev [3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)propionat-(S)-3'-metil-2'-(pentanoil{2"(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat] hemipentahidrat.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178141 | 2015-07-23 | ||
| EP16739146.5A EP3325013B2 (de) | 2015-07-23 | 2016-07-15 | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und einem angiotensin aii-antagonisten und ihre verwendung |
| PCT/EP2016/066891 WO2017013010A1 (de) | 2015-07-23 | 2016-07-15 | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20201932T1 HRP20201932T1 (hr) | 2021-02-05 |
| HRP20201932T4 true HRP20201932T4 (hr) | 2024-02-16 |
Family
ID=53758071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201932TT HRP20201932T4 (hr) | 2015-07-23 | 2016-07-15 | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11166932B2 (hr) |
| EP (1) | EP3325013B2 (hr) |
| JP (1) | JP6849618B2 (hr) |
| CN (3) | CN113750102A (hr) |
| CA (1) | CA2989740C (hr) |
| DK (1) | DK3325013T4 (hr) |
| ES (1) | ES2839248T5 (hr) |
| FI (1) | FI3325013T4 (hr) |
| HR (1) | HRP20201932T4 (hr) |
| HU (1) | HUE052337T2 (hr) |
| LT (1) | LT3325013T (hr) |
| SI (1) | SI3325013T2 (hr) |
| WO (1) | WO2017013010A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
| WO2019022436A2 (ko) * | 2017-07-27 | 2019-01-31 | 에리슨제약(주) | Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물 |
| WO2019081456A1 (en) * | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| CN112055584A (zh) * | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| WO2021230664A1 (ko) * | 2020-05-12 | 2021-11-18 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
| KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
| CN115317478B (zh) * | 2022-08-26 | 2023-05-02 | 宁波大学 | 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| AU736303B2 (en) | 1996-10-14 | 2001-07-26 | Bayer Aktiengesellschaft | New heterocyclylmethyl-substituted pyrazol derivates |
| DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| CN1332943C (zh) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10054278A1 (de) | 2000-11-02 | 2002-05-08 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose |
| DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| EP1339716B1 (de) | 2000-11-22 | 2004-11-03 | Bayer HealthCare AG | lactam-substituierte pyrazolopyridinderivate |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| DE10109859A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
| DE10109858A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
| DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| US20030016677A1 (en) | 2001-07-17 | 2003-01-23 | Karl Mauritz | Fabric bus architeture |
| EP1452521A4 (en) * | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR |
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| US7332883B1 (en) * | 2005-06-17 | 2008-02-19 | Marvell International Ltd. | Method and apparatus for initializing operation of a disk drive |
| DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
| DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
| DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| EP2197551B1 (en) | 2007-09-06 | 2016-12-28 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| WO2009071504A1 (en) | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
| EP2264017A4 (en) | 2008-04-04 | 2011-07-27 | Takeda Pharmaceutical | Heterocyclic derivative and its use |
| DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
| WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| SG185690A1 (en) * | 2010-05-26 | 2012-12-28 | Bayer Ip Gmbh | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). |
| PE20130222A1 (es) | 2010-05-27 | 2013-03-14 | Merck Sharp & Dohme | Activadores de guanilato ciclasa soluble |
| BR112012033341B1 (pt) | 2010-06-30 | 2022-08-23 | Cyclerion Therapeutics, Inc | Estimulantes de sgc |
| ES2572638T3 (es) | 2010-07-09 | 2016-06-01 | Bayer Intellectual Property Gmbh | 4-Aminopirimidinas condensadas y su uso como estimuladores de la guanilatociclasa soluble |
| BR112013000596A2 (pt) | 2010-07-09 | 2019-09-24 | Bayer Intelectual Property Gmbh | piridinas e tiazinas fusionadas e seus usos. |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
| JP5878546B2 (ja) | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| JP5989660B2 (ja) | 2010-12-07 | 2016-09-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換１−ベンジルシクロアルキルカルボン酸およびその使用 |
| DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| WO2012143510A1 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
| DE102011075398A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridazine und ihre Verwendung |
| JP5976788B2 (ja) | 2011-05-06 | 2016-08-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用 |
| ES2597034T3 (es) | 2011-05-30 | 2017-01-13 | Astellas Pharma Inc. | Compuesto de imidazopiridina |
| CN103906752B (zh) | 2011-07-06 | 2016-08-24 | 拜耳知识产权有限责任公司 | 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途 |
| US8859569B2 (en) | 2011-09-02 | 2014-10-14 | Bayer Pharma Aktiengesellschaft | Substituted annellated pyrimidines and use thereof |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| JP6140738B2 (ja) | 2012-03-06 | 2017-05-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アザ二環およびその使用 |
| DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
| KR102137517B1 (ko) | 2012-07-20 | 2020-07-24 | 바이엘 파마 악티엔게젤샤프트 | 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도 |
| CA2879456A1 (en) | 2012-07-20 | 2014-01-23 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralincarboxylic acids and use thereof |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| EP2927231B1 (en) | 2012-11-30 | 2017-09-20 | Astellas Pharma Inc. | Imidazopyridine compounds |
| BR112015019571A2 (pt) | 2013-02-21 | 2017-07-18 | Adverio Pharma Gmbh | formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila |
| AU2014222739A1 (en) | 2013-03-01 | 2015-09-03 | Bayer Pharma Aktiengesellschaft | Trifluormethyl-substituted ring-fused pyrimidines and use thereof |
| EP2961754B1 (de) | 2013-03-01 | 2016-11-16 | Bayer Pharma Aktiengesellschaft | Benzyl-substituierte pyrazolopyridine und ihre verwendung |
| PT2970243T (pt) | 2013-03-15 | 2020-03-05 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
| CN105339368B (zh) * | 2013-06-04 | 2017-08-15 | 拜耳制药股份公司 | 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途 |
| WO2015004105A1 (de) | 2013-07-10 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Benzyl-1h-pyrazolo[3,4-b]pyridine und ihre verwendung |
| KR101473813B1 (ko) | 2013-07-15 | 2014-12-17 | 주식회사 지오스에어로젤 | 원단용 기능성 용액 주입시스템 및 이를 이용한 원단의 제작방법 |
| WO2015008885A1 (ko) | 2013-07-19 | 2015-01-22 | 엠앤디(주) | 자궁경부암 진단 방법 및 그 진단용 키트 |
| JP2016527295A (ja) | 2013-08-08 | 2016-09-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換イミダゾ［１，２−ａ］ピラジンカルボキサミドおよびその使用 |
| EP3030562B1 (de) | 2013-08-08 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung |
| WO2016087342A1 (de) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
| WO2016124564A1 (de) * | 2015-02-05 | 2016-08-11 | Bayer Pharma Aktiengesellschaft | N-substituierte 8-[(2,6-difluorbenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamid-derivate als stimulatoren der löslichen guanylatcyclase (sgc) zur behandlung von kardiovaskulären erkrankungen |
| SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
-
2016
- 2016-07-15 SI SI201630938T patent/SI3325013T2/sl unknown
- 2016-07-15 JP JP2017567712A patent/JP6849618B2/ja active Active
- 2016-07-15 US US15/746,624 patent/US11166932B2/en active Active
- 2016-07-15 LT LTEP16739146.5T patent/LT3325013T/lt unknown
- 2016-07-15 HU HUE16739146A patent/HUE052337T2/hu unknown
- 2016-07-15 EP EP16739146.5A patent/EP3325013B2/de active Active
- 2016-07-15 CN CN202111173343.4A patent/CN113750102A/zh active Pending
- 2016-07-15 FI FIEP16739146.5T patent/FI3325013T4/fi active
- 2016-07-15 CN CN202111173325.6A patent/CN113712969A/zh active Pending
- 2016-07-15 HR HRP20201932TT patent/HRP20201932T4/hr unknown
- 2016-07-15 CN CN201680043258.7A patent/CN108430510B/zh active Active
- 2016-07-15 WO PCT/EP2016/066891 patent/WO2017013010A1/de active Application Filing
- 2016-07-15 CA CA2989740A patent/CA2989740C/en active Active
- 2016-07-15 DK DK16739146.5T patent/DK3325013T4/da active
- 2016-07-15 ES ES16739146T patent/ES2839248T5/es active Active
-
2021
- 2021-10-05 US US17/494,421 patent/US20220023246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3325013T1 (sl) | 2020-11-30 |
| EP3325013B1 (de) | 2020-09-23 |
| SI3325013T2 (sl) | 2023-11-30 |
| CN108430510B (zh) | 2021-10-29 |
| CA2989740A1 (en) | 2017-01-26 |
| LT3325013T (lt) | 2020-11-10 |
| EP3325013B2 (de) | 2023-07-19 |
| CN113750102A (zh) | 2021-12-07 |
| ES2839248T5 (es) | 2024-02-22 |
| US20190125709A1 (en) | 2019-05-02 |
| CA2989740C (en) | 2023-07-11 |
| WO2017013010A1 (de) | 2017-01-26 |
| JP2018520151A (ja) | 2018-07-26 |
| HUE052337T2 (hu) | 2021-04-28 |
| JP6849618B2 (ja) | 2021-03-24 |
| CN113712969A (zh) | 2021-11-30 |
| CN108430510A (zh) | 2018-08-21 |
| US11166932B2 (en) | 2021-11-09 |
| DK3325013T4 (da) | 2023-10-16 |
| US20220023246A1 (en) | 2022-01-27 |
| DK3325013T3 (da) | 2020-12-14 |
| ES2839248T3 (es) | 2021-07-05 |
| HRP20201932T1 (hr) | 2021-02-05 |
| FI3325013T4 (fi) | 2023-10-11 |
| EP3325013A1 (de) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201932T4 (hr) | Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| IN2014MN01839A (hr) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| EA201691404A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов бромодомена | |
| SA518391836B1 (ar) | تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| SG10201806565SA (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| GEP20186938B (en) | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | |
| EP3915566C0 (en) | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE, CONTAINING, AS ACTIVE INGREDIENT, TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| MA43066A (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
| EA201591499A1 (ru) | Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| WO2012101065A3 (en) | Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| RU2016145066A (ru) | Композиция для предотвращения или лечения жировых болезней печени | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| JP2016515550A5 (hr) |